<DOC>
	<DOCNO>NCT02408185</DOCNO>
	<brief_summary>Phase II clinical trial , open-labelled , prospective single-center study direct obtain blood sample experimental detailed condition order compare optimize dose colistin critically ill patient suffer infection indication colistin would accept accord normal local protocol severe infection treatment .</brief_summary>
	<brief_title>Optimization Dose Study Pharmacokinetics Pharmacodynamics Colistin Critically Ill Patients</brief_title>
	<detailed_description />
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>More 60 Kg weigh Patients direct treatment colistin recommend antimicrobial treatment protocol hospital treat follow serious infection cause carbapenems resistant A. baumannii : ( ) bacteremia ; ( ii ) nosocomial pneumonia ( iii ) infection skin soft tissue ( cellulitis , abscess infect ulcer ) . Written inform consent form . Refractory shock illness expectative life Ë‚ 48 hour recruitment ; Patient declare resuscitation maneuver ; Suspicion demonstration endocarditis , osteomyelitis , meningitis ; Known hypersensitivity polymyxin ; Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>infection</keyword>
	<keyword>multidrug resistant Gram negative bacteria ( MDR-GNB )</keyword>
	<keyword>Skin infection</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Bacteriemia</keyword>
	<keyword>Nosocomial infection</keyword>
</DOC>